Text Size

Austrian Multivessel Taxus-Stent Registry (AUTAX)

This study has been completed.
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00738686
First received: August 19, 2008
Last updated: August 20, 2008
Last verified: August 2008
History of Changes
  Purpose

The aim of AUTAX study is to investigate the frequency of MACCE in patients with multivessel disease and multiple Taxus stent implantations in the "real world" stenting at 30 days, 6 and 12 months at 2 year follow-up. Because multivessel stenting using DES has been limited due to economic considerations, the secondary aim is to enhance experience in multivessel stenting with drug-eluting stents in order to improve short- and long-term outcomes of the patients with severe multiple coronary artery stenoses.

The objectives of the study are:

  1. To determine the frequency of MACCE at 30-day, 6 and 12-month and at 2 year clinical follow-up after multivessel intervention with drug-eluting stents in a prospective patient cohort..
  2. To determine the rate of in-stent restenosis, target lesion and target vessel revascularization (angiographic measures) 6 months in patients with multiple DESs in multiple lesions.
  3. To investigate the clinical and angiographic outcomes after implantation of multiple DESs in the subgroup of patients with accompanying diseases (diabetes mellitus, renal insufficiency) with known high restenosis and late complication rate.
  4. To evaluate potential cost burden in attempting a strategy of complete revascularization by multiple DES in patients with multivessel disease.

Condition Intervention Phase
Coronary Artery Disease
 Device: Intracoronary stent implantation
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Austrian Multivessel Taxus-Stent Registry

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Medical University of Vienna:

Primary Outcome Measures:
  • Incidence of MACCE, defined as all-cause death, nonfatal acute myocardial infarction (AMI) target vessel revascularization (TVR) and cerebrovascular event during the two-year clinical follow-up (FUP) [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Break-down primary endpoints at the 2-year FUP, as the rate of TVR, non-fatal AMI, all-cause death, stroke and the composite of death and AMI [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]
  • Incidence of 30-days, 6-mo and 1-year MACCE [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Acute, subacute and late thrombosis rates [ Time Frame: 2 year ] [ Designated as safety issue: Yes ]
  • Angiographic end-points as the binary restenosis rate per lesion (defined as diameters stenosis ≥ 50%), in-stent and proximal and distal in-lesion late lumen loss [ Time Frame: 6-month ] [ Designated as safety issue: No ]

Enrollment: 441
Study Start Date: June 2004
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Single-arm study, no placebo or control group
 Device: Intracoronary stent implantation
Taxus stent implantation in patients with multivessel coronary artery disease
Other Names:
  • Taxus Express
  • Taxus Liberte

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • symptomatic coronary multivessel disease
  • possible percutaneous complete coronary revascularization
  • age >18 year
  • significant coronary lesion at least in 2 vessels

Exclusion Criteria:

  • acute myocardial infarction within 48 hours
  • contraindications to clopidogrel, aspirin, heparin and taxol
  • pregnancy or lack of protection against pregnancy or breast-feeding during the study
  • hemorrhagic diathesis
  • platelet count <100.000/ml3
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00738686

Locations
Austria
Landeskrankenhaus
Bruck an der Mur, Austria
Department of Interventional Cardiology, Academic Hospital
Feldkirch, Austria
Landeskrankenhaus Graz-West
Graz, Austria
Allgemeines Krankenhaus der Stadt Linz
Linz, Austria
Krankenhaus Barmherzigen Schwestern
Linz, Austria
St. Johannes Spital
Salzburg, Austria
Rudolfstiftung
Vienna, Austria
Sponsors and Collaborators
Medical University of Vienna
Investigators
Principal Investigator: Helmut-Dietmar Glogar, MD FESC Dept. Cardiology, Medical University of Vienna, Vienna, Austria
  More Information

No publications provided by Medical University of Vienna

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Helmut-Dietmar Glogar, Dept. Cardiology, Medical University of Vienna, Austria
ClinicalTrials.gov Identifier: NCT00738686     History of Changes
Other Study ID Numbers: AUTAX
Study First Received: August 19, 2008
Last Updated: August 20, 2008
Health Authority: Austria: Ethikkommission

Keywords provided by Medical University of Vienna:
coronary artery disease
drug-eluting stent
percutaneous coronary intervention
 major adverse cardiac event
in-stent restenosis
stent thrombosis

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
 Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on June 18, 2013